Progress in non-surgical local treatment of colorectal cancer liver metastases and its application prospects

doi:10.3877/cma.j.issn.2095-5782.2023.01.010

Abstract

Abstract:

Liver is the most common site of metastasis for colorectal cancer (CRC), which is highly malignant, aggressive and has poor prognosis. About 50% of patients develop liver metastases during the course of the disease, and liver metastases are also a major cause of death. Surgical resection is still the main cure method for colorectal cancer liver metastases (CRCLM), but only less than 20% of patients have access to radical surgery. Therefore, non-surgical local treatment combined with comprehensive treatment is essential. With the concept of individualized treatment and Multiple disciplinary team (MDT), as well as the rapid development of non-surgical local treatment, the survival time of patients with liver metastases of colorectal cancer has been significantly prolonged, and even some patients with initial inoperable resection have been successfully converted to R0 resection through non-surgical local treatment. This article reviews the research progress on non-surgical local treatment of CRCLM in recent years.

Key words: Colorectal cancer liver metastases, Local treatments, Ablation treatment, Chemotherapy embolization, Radiation therapy

Haoyuan Li, Ming Huang, Jinmei Zhou, Bohan Song, Jinfeng Bai, Qijie Wu, Rong Ding. Progress in non-surgical local treatment of colorectal cancer liver metastases and its application prospects[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(01): 55-61.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2023.01.010

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2023/V11/I01/55

References 68

[1]	Siegel RL, Miller KD, Goding SA, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
[2]	刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[3]	中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(3): 543-553.
[4]	Oki E, Ando K, Nakanishi R, et al. Recent advances in treatment for colorectal liver metastasis[J]. Ann Gastroenterol Surg, 2018, 2(3): 167-175.
[5]	Mitchell D, Puckett Y, Nguyen QN. Literature review of current management of colorectal liver metastasis[J]. Cureus, 2019, 11(1): e3940.
[6]	Wei N, Zhang B, Wang Y, et al. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis[J]. Clin Transl Oncol, 2019, 21(4): 443-450.
[7]	Ren Y, Chen L, Huang S, et al. Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis[J]. Abdom Radiol (NY), 2020, 45(9): 2862-2870.
[8]	Yang D, Zhuang B, Lin M, et al. Primary tumour location is an important prognostic factor in colorectal cancer liver metastases following radiofrequency ablation[J]. Clin Radiol, 2020, 75(12): 961. e961-961. e969.
[9]	Tinguely P, Dal G, Bottai M, et al. Microwave ablation versus resection for colorectal cancer liver metastases - a propensity score analysis from a population-based nationwide registry[J]. Eur J Surg Oncol, 2020, 46(3): 476-485.
[10]	Fiorentini G, Sarti D, Aliberti C, et al. Chemoembolization in conjunction with bevacizumab: preliminary results[J]. J Vasc Interv Radiol, 2018, 29(9): 1236-1239.
[11]	Larsen FO, Jensen BV, Nørgaard HH, et al. Intrahepatic oxaliplatin and systemic 5-fu^+/- cetuximab in chemo-naïve patients with liver metastases from colorectal cancer[J]. Oncology, 2019, 96(6): 299-308.
[12]	李学敏, 王皓, 王俊杰. 结直肠癌肝转移立体定向消融放疗[J]. 临床肝胆病杂志, 2021, 37(3): 522-526.
[13]	Vietti VN, Duran R, Demartines N, et al. Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation[J]. Int J Hyperthermia, 2018, 34(7): 1020-1028.
[14]	Imai K, Allard MA, Castro BC, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases[J]. Br J Surg, 2017, 104(5): 570-579.
[15]	Ruers T, Van CF, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phaseⅡ trial[J]. J Natl Cancer Inst, 2017, 109(9): djx015.
[16]	Ruers T, Punt C, Van CF, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phaseⅡstudy (EORTC 40004)[J]. Ann Oncol, 2012, 23(10): 2619-2626.
[17]	Han K, Kim JH, Yang SG, et al. A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases[J]. Radiology, 2021, 298(1): 212-218.
[18]	徐燕军, 侯瑞, 胡兵. 热沉没效应对射频消融的影响及削减方法[J]. 肿瘤影像学, 2017, 26(06): 422-425.
[19]	Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control[J].J Vasc Interv Radiol, 2018, 29(2): 268-275. e261.
[20]	Takahashi H, Kahramangil B, Kose E, et al. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases[J]. HPB (Oxford), 2018, 20(12): 1157-1162.
[21]	Ierardi AM, Floridi C, Fontana F, et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation[J]. Radiol Med, 2013, 118(6): 949-961.
[22]	Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review[J]. Colorectal Dis, 2011, 13(9): e252-265.
[23]	Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model[J]. Medicine (Baltimore), 2015, 94(9): e580.
[24]	Dijkstra M, Nieuwenhuizen S, Puijk RS, et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an amsterdam colorectal liver met registry (AmCORE) based study[J]. Cancers (Basel), 2021, 13(11): 2769.
[25]	Philips P, Groeschl RT, Hanna EM, et al. Single-stage resection and microwave ablation for bilobar colorectal liver metastases[J]. Br J Surg, 2016, 103(8): 1048-1054.
[26]	Takahashi H, Akyuz M, Kahramangil B, et al. A comparison of the Initial cost associated with resection versus laparoscopic radiofrequency ablation of small solitary colorectal liver metastasis[J]. Surg Laparosc Endosc Percutan Tech, 2018, 28(6): 371-374.
[27]	Tamai H, Okamura J. New next-generation microwave thermosphere ablation for small hepatocellular carcinoma[J]. Clin Mol Hepatol, 2021, 27(4): 564-574.
[28]	De CF, Calandri M, Della CA, et al. Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study[J]. Eur Radiol, 2022 Jun;32(6): 4147-4159.
[29]	Vogl TJ, Dommermuth A, Heinle B, et al. Colorectal cancer liver metastases: long-term survival and progression-free survival after thermal ablation using magnetic resonance-guided laser-induced interstitial thermotherapy in 594 patients: analysis of prognostic factors[J]. Invest Radiol, 2014, 49(1): 48-56.
[30]	Puls R, Langner S, Rosenberg C, et al. Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5-year survival[J]. J Vasc Interv Radiol, 2009, 20(2): 225-234.
[31]	Christophi C, Nikfarjam M, Malcontenti WC, et al. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy[J]. World J Surg, 2004, 28(10): 987-994.
[32]	Ng KM, Chua TC, Saxena A, et al. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases[J]. Ann Surg Oncol, 2012, 19(4): 1276-1283.
[33]	Di MM, Rompianesi G, Mora GI, et al. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases[J]. Eur J Surg Oncol, 2020, 46(5): 772-781.
[34]	韩宗宏, 曹建民, 史东宏. 肿瘤冷冻消融免疫效应研究的进展[J]. 介入放射学杂志, 2013, 22(12): 1055-1058.
[35]	周福波, 于晓玲, 梁萍, 等. 热消融治疗在结直肠癌肝转移中的应用进展[J]. 解放军医学院学报, 2017, 38(3): 259-262.
[36]	Schicho A, Niessen C, Haimerl M, et al. Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases[J]. Cancer Manag Res, 2019, 11: 317-322.
[37]	Meijerink MR, Ruarus AH, Vroomen L, et al. Irreversible electroporation to treat unresectable colorectal liver metastases (COLDFIRE-2): a phaseⅡ, two-center, single-arm clinical trial[J]. Radiology, 2021, 299(2): 470-480.
[38]	Yang T, Ng DM, Du N, et al. HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phaseⅠclinical trial[J]. Surg Endosc, 2021, 35(5): 2306-2315.
[39]	徐缨龙, 胡建容, 李世红, 等. 手术切除、射频消融及海扶刀治疗结直肠癌肝转移患者的不同预后比较[J]. 实用医院临床杂志, 2020, 17(1): 103-106.
[40]	李智岗, 黄景香, 李顺宗, 等. 肝转移瘤的血供[J]. 北京大学学报(医学版), 2008, (2): 146-150.
[41]	Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof[J]. Future Oncol, 2015, 11(9): 1421-1428.
[42]	Kwan J, Pua U. Review of intra-arterial therapies for colorectal cancer liver metastasis[J]. Cancers (Basel), 2021, 13(6): 1371.
[43]	王宏, 郭广洋. 经导管动脉栓塞化疗为基础的多烯紫杉醇联合方案治疗结直肠癌肝转移效果分析[J]. 现代消化及介入诊疗, 2016, 21(1): 35-37, 42.
[44]	含笑. 肝转移癌TACE疗效评价及影响因素分析[D]. 安徽医科大学, 2013.
[45]	Boilève A, De CA, Larive A, et al. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases[J]. Eur J Cancer, 2020, 138: 89-98.
[46]	Doussot A, Kemeny NE, D'Angelica MI. Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases[J]. Hepat Oncol, 2015, 2(3): 275-290.
[47]	Datta J, Narayan RR, Kemeny NE, et al. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review[J]. JAMA Surg, 2019, 154(8): 768-776.
[48]	Allard MA, Adam R, Giuliante F, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases[J]. Br J Cancer, 2017, 117(5): 604-611.
[49]	Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322.
[50]	Dagoglu N, Karaman S, Caglar HB, et al. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases[J]. Cureus, 2019, 11(2): e4103.
[51]	Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial[J]. Lancet Oncol, 2015, 16(7): 795-803.
[52]	裴苏. 肺、肝转移放射治疗价值的研究[D]. 广西医科大学, 2017.
[53]	营巧玲, 何泽来, 郭术楠, 等. 结直肠癌寡转移三维适形调强放疗的临床评价[J]. 中华全科医学, 2019, 17(11): 1802-1805.
[54]	He X, Zhang P, Li Z, et al. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: a single-center study[J]. Medicine (Baltimore), 2018, 97(40): e12601.
[55]	王伟, 王跃伟, 刘建波, 等. 42例消化系恶性肿瘤肝转移中应用三维适形放疗的临床疗效[J]. 世界华人消化杂志, 2016, 24(1): 126-130.
[56]	Chow FC, Chok KS. Colorectal liver metastases: an update on multidisciplinary approach[J]. World J Hepatol, 2019, 11(2): 150-172.
[57]	Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review[J]. Radiother Oncol, 2018, 129(3): 427-434.
[58]	Wang TH, Huang PI, Hu YW, et al. Combined yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: from clinical aspects to dosimetry[J]. PLoS One, 2018, 13(1): e0190098.
[59]	Cortesi E, Caponnetto S, Masi G, et al. Efficacy and tolerability of selective internal radiotherapy with yttrium-90 as consolidation treatment after chemotherapy in metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2020, 19(4): e272-e276.
[60]	Gibbs P, Heinemann V, Sharma NK, et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies[J]. Clin Colorectal Cancer, 2018, 17(4): e617-e629.
[61]	Winter H, Rassam J, Virdee PS, et al. Hepatic resection following selective internal radiation therapy for colorectal cancer metastases in the FOXFIRE clinical trial: clinical outcomes and distribution of microspheres[J]. Cancers (Basel), 2019, 11(8):1155.
[62]	Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT)[J]. Cardiovasc Intervent Radiol, 2021, 44(1): 21-35.
[63]	张迎强, 林岩松. ⁹⁰Y微球选择性内放射治疗在结直肠癌肝转移中的应用及研究进展[J]. 中国癌症杂志, 2021, 31(8):762-768.
[64]	刘振华, 蔡联明, 陈爱林, 等. CT引导下¹²⁵I粒子植入治疗结直肠癌异时性肝转移的临床研究[J]. 当代医学, 2021, 27(35): 26-28.
[65]	陈磊, 郑传胜. 碘125粒子植入联合其它疗法在各期肝癌治疗中的应用[J]. 介入放射学杂志, 2019, 28(9): 910-913.
[66]	黄慧娴, 王国栋, 赵剑波, 等. ¹²⁵I粒子植入联合化学治疗干预晚期结直肠癌肝转移瘤效果[J]. 中国介入影像与治疗学, 2020, 17(6): 329-332.
[67]	郭甲民, 刘伟. 超声引导下¹²⁵I粒子植入联合射频消融术对结直肠癌肝转移的疗效研究[J]. 实用癌症杂志, 2019, 34(11): 1813-1815.
[68]	秦新裕, 冯青阳, 许剑民. 重视并规范化开展结直肠癌肝转移多学科综合治疗[J]. 中国实用外科杂志, 2013, 33(8): 619-621.

Please choose a citation manager

Content to export